New hope for Hard-to-Treat breast cancer: experimental combo enters phase 2
NCT ID NCT07509515
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, QLC5513, alone or with another drug (QL1706) in 60 women with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants will receive the drugs intravenously and be monitored for safety and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter immunotherapy course may be enough for some breast cancer patients — a major trial puts it to the test
- Leftover tumor after breast cancer treatment: a hidden risk revealed
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Could a modified protein help immunotherapy fight a tough breast cancer?
- Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
- New hope for Hard-to-Treat breast cancer: drug combo trial launches